Remarks: Hydroxychloroquine is Effective and Safe for the Treatment of COVID-19, and May be Universally Effective When Used Early Before Hospitalization and the CONCLUSION WAS HCQ is consistently effective against COVID-19 when used early in the outpatient setting, it is overall effective against COVID-19, it has not produced worsening, it is safe. FULL STORY HERE: https://www.4cmitv.com/2020/09/09/2020-sep-study-says-hydroxychloroquine-is-effective-and-safe-for-the-treatment-of-covid-19-researchgate/
Researchgate: Hydroxychloroquine is Effective and Safe for the Treatment of COVID-19, and May be Universally Effective When Used Early Before Hospitalization: A Systematic Review
RELEASE HCQ STOP-INTERFERING WITH OUR HEALTH
INTRODUCTION: Hydroxychloroquine (HCQ) has shown efficacy against COVID-19 in some but not all studies. We hypothesized that systematic review would show HCQ to be: effective against COVID-19, more effective used earlier, not associated with worsening, and safe.
METHODS: We searched PubMed, Cochrane, EmBase, Google Scholar, and Google for all reports on hydroxychloroquine as a treatment for COVID-19 patients. This included pre-prints and preliminary reports on larger COVID-19 studies. We examined the studies for efficacy, time of administration and safety.
RESULTS: HCQ was found consistently effective against COVID-19 when used early, in the outpatient setting. It was found overall effective. No credible study found worse outcomes with HCQ use.
No mortality or other serious safety issue was found.
CONCLUSIONS:
HCQ is consistently effective against COVID-19 when used early in the outpatient setting, it is overall effective against COVID-19, it has not produced worsening, it is safe.
Studies that showed worse results with HCQ Table 3
Study results by Time of Treatment Initiation Table 5
Table 1- Studies that showed positive results with HCQ
Table 1 – Page 1/5
Table 1 – Page 2/5
Table 1 – Page 3/5
FOOTNOTE TABLE 1:
*AE, adverse event; AZ, Azithromycin; HCQ, hydroxychloroquine; LPV/r, lopinavir/ ritonavir ; SAE, serious adverse event; ZN, Zinc
Table 1 – Page 4/5
Table 1 – Page 5/5
.
Table 2 – Studies that showed no improvement with HCQ
Table 2 – Page 1/5
Table 2 – Page 2/5
Table 2 – Page 3/5
FOOTNOTE TABLE 2:
*AE, adverse event; AZ, Azithromycin; HCQ, hydroxychloroquine; LPV/r, lopinavir/ ritonavir ; SAE, serious adverse event; ZN, Zinc
Table 2 – Page 4/5
Table 2 – pg 5/5
.
Table 3 – Studies that showed worse results with HCQ
FOOTNOTE TABLE 3:
*AE, adverse event; AZ, Azithromycin; HCQ, hydroxychloroquine; LPV/r, lopinavir/ ritonavir ; SAE, serious adverse event; ZN, Zinc
.
Table 3 – Page 1/1
.
.
Table 4- Comparison of treatments, setting, and results
C1R2
C1R3
Table 5- Study results by Time of Treatment Initiation
FOOTNOTE TABLE 5: *Both the outpatient and w/in 48 hrs of hospitalization groups each had 2 studies that trended towards positive results but did not achieve statistical significance. This table has these studies grouped with the good results
Table 5 – Page 1/1
.
.
EfHCQ9-4
Hashtags: #4cminewswire, #Hydroxychloroquine, #HCQ, #Zinc, #Azithromycin, #Researchgate, #COVID19, #Coronavirus, #4cminews, #4CMiTV, #4CM2020SEP01,
Tags: 4cminewswire, Hydroxychloroquine, HCQ, Zinc, Azithromycin, Researchgate, COVID-19, Coronavirus, 4cminews, 4CMiTV, #4CM2020SEP01,
4CMINEWS SOCIAL MEDIA:
Gab: https://gab.com/4cminewswire/posts/104834445603120673
Gab AU: https://gab.com/4cminewswire/posts/104834449954908120
Telegram: @Newswire4cm
Twitter: https://twitter.com/4cminews/status/1303639671000371200?s=20
Parler: https://share.par.pw/post/181fe88f6c3143df838c832cb3ab0a51
Dailymotion & Facebook: DEFUNCT SOCIAL MEDIA PLATFORM
.
.
Situation Vacant